| __timestamp | Bausch Health Companies Inc. | BioMarin Pharmaceutical Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 2254600000 | 129764000 |
| Thursday, January 1, 2015 | 2645000000 | 152008000 |
| Friday, January 1, 2016 | 2611000000 | 209620000 |
| Sunday, January 1, 2017 | 2548000000 | 241786000 |
| Monday, January 1, 2018 | 2351000000 | 315264000 |
| Tuesday, January 1, 2019 | 2350000000 | 359466000 |
| Wednesday, January 1, 2020 | 2249000000 | 524272000 |
| Friday, January 1, 2021 | 2394000000 | 470515000 |
| Saturday, January 1, 2022 | 2364000000 | 483669000 |
| Sunday, January 1, 2023 | 2559000000 | 577065000 |
| Monday, January 1, 2024 | 580235000 |
Igniting the spark of knowledge
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. This analysis delves into the cost of revenue trends for BioMarin Pharmaceutical Inc. and Bausch Health Companies Inc. from 2014 to 2023. Over this period, Bausch Health consistently reported a higher cost of revenue, averaging around $2.43 billion annually, compared to BioMarin's $346 million. However, BioMarin's cost of revenue grew by approximately 345% from 2014 to 2023, indicating a significant expansion in operations. In contrast, Bausch Health's cost of revenue remained relatively stable, with a modest increase of about 13% over the same period. This stability suggests a mature operational model, while BioMarin's growth reflects its aggressive market expansion. Understanding these trends provides valuable insights into each company's strategic focus and operational efficiency, crucial for investors and stakeholders in the pharmaceutical industry.
Cost Insights: Breaking Down Eli Lilly and Company and Bausch Health Companies Inc.'s Expenses
Cost of Revenue Comparison: Novo Nordisk A/S vs Bausch Health Companies Inc.
Cost of Revenue Trends: Merck & Co., Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue Comparison: Pfizer Inc. vs BioMarin Pharmaceutical Inc.
Cost of Revenue: Key Insights for United Therapeutics Corporation and Bausch Health Companies Inc.
Cost of Revenue Comparison: Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.
Cost Insights: Breaking Down Intra-Cellular Therapies, Inc. and Bausch Health Companies Inc.'s Expenses
Cost of Revenue Trends: BioMarin Pharmaceutical Inc. vs Sarepta Therapeutics, Inc.
BioMarin Pharmaceutical Inc. vs Catalent, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Grifols, S.A. and Bausch Health Companies Inc.
Cost of Revenue Comparison: Ionis Pharmaceuticals, Inc. vs Bausch Health Companies Inc.
CRISPR Therapeutics AG vs Bausch Health Companies Inc.: Efficiency in Cost of Revenue Explored